Replies to post #427 on Equity Field Notes from temporal sources

[DanWebzster]

BXRX is a specialty pharma spun out of REPH during 11/19

Its lead asset is the recently approved Meloxicam for pain control in acute settings.

One of the reasons this stock has been crushed in 2020 is management's decision to implement a cashless warrant conversion. In essence, BXRX issued 9.8M shares w/o getting a dime for them.

On 8/20 BXRX current assets were ~20M

Meloxicam is already in 50 of the 2000 largest hospitals in the U.S.
If it can get into ~250 hospitals, that would be an indication of the potential for 100M revenue.

I would be interested in buying an offering if conducted before the end of 2020. After tax loss season, I would put it on my list of Low-Floaters if it did a reverse split in 2021.

[DanWebzster]

XENE is behaving bullishly here toward the end of 2020. An analyst at Bloom Burton has it as his top pick for 2021.

Here's a refresh on the XENE pipeline:

* X1101 is the lead program. It's a more targeted version of the battleground epilepsy therapy, Egozabine. The pace of enrollment in Ph2B is picking up. It's partnered with NBIX

* X901 is a formulation that contains Egozabine intended to treat pediatric epilepsy patients. XENE is currently working on a Ph2 protocol.

* X496 contains active ingredients of Egozabine. This formulation is Ph3-ready. The target market is children with a specific mutation. XENE is working on identifying every child with this mutation.

* X007 is a formula containing Flunarizine, a drug that has been used Ex-USA for decades. XENE has acquired the rights to this drug for the USA. It's being developed for a rare pediatric disease.